| Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial M Paul, GL Daikos, E Durante-Mangoni, D Yahav, Y Carmeli, YD Benattar, ... The lancet Infectious diseases 18 (4), 391-400, 2018 | 526 | 2018 |
| Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis O Zusman, S Altunin, F Koppel, Y Dishon Benattar, H Gedik, M Paul Journal of Antimicrobial Chemotherapy 72 (1), 29-39, 2016 | 179 | 2016 |
| Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial Y Dickstein, J Lellouche, M Ben Dalak Amar, D Schwartz, A Nutman, ... Clinical Infectious Diseases 69 (5), 769-776, 2019 | 100 | 2019 |
| Colistin plus meropenem for carbapenem-resistant Gram-negative infections: In vitro synergism is not associated with better clinical outcomes A Nutman, J Lellouche, E Temkin, G Daikos, A Skiada, ... Clinical Microbiology and Infection 26 (9), 1185-1191, 2020 | 70 | 2020 |
| The effectiveness and safety of high-dose colistin: prospective cohort study YD Benattar, M Omar, O Zusman, D Yahav, Y Zak-Doron, S Altunin, ... Clinical Infectious Diseases 63 (12), 1605-1612, 2016 | 60 | 2016 |
| Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant … Y Dickstein, L Leibovici, D Yahav, N Eliakim-Raz, GL Daikos, A Skiada, ... BMJ open 6 (4), e009956, 2016 | 51 | 2016 |
| The association between empirical antibiotic treatment and mortality in severe infections caused by carbapenem-resistant gram-negative bacteria: a prospective study Y Zak-Doron, Y Dishon Benattar, I Pfeffer, GL Daikos, A Skiada, ... Clinical infectious diseases 67 (12), 1815-1823, 2018 | 44 | 2018 |
| Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria AN Kristoffersson, V Rognås, MJE Brill, Y Dishon-Benattar, ... Clinical Microbiology and Infection 26 (12), 1644-1650, 2020 | 29 | 2020 |
| Duration of antibiotic treatment for Gram-negative bacteremia–Systematic review and individual participant data (IPD) meta-analysis A Turjeman, E von Dach, J Molina, E Franceschini, F Koppel, D Yelin, ... EClinicalMedicine 55, 2023 | 20 | 2023 |
| Colistin resistance development following colistin-meropenem combination therapy versus colistin monotherapy in patients with infections caused by carbapenem-resistant organisms Y Dickstein, J Lellouche, D Schwartz, A Nutman, N Rakovitsky, ... Clinical Infectious Diseases 71 (10), 2599-2607, 2020 | 20 | 2020 |
| Prevalence and clinical consequences of colistin heteroresistance and evolution into full resistance in carbapenem-resistant Acinetobacter baumannii H Kon, A Hameir, A Nutman, E Temkin, A Keren Paz, J Lellouche, ... Microbiology Spectrum 11 (3), e05093-22, 2023 | 9 | 2023 |
| Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance S Frenk, E Temkin, MN Lurie-Weinberger, A Keren-Paz, R Rov, ... Journal of Antimicrobial Chemotherapy 77 (4), 934-943, 2022 | 9 | 2022 |
| Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity V Daitch, M Paul, GL Daikos, E Durante-Mangoni, D Yahav, Y Carmeli, ... BMC Infectious Diseases 21, 1-9, 2021 | 4 | 2021 |
| Optimizing patient recruitment into clinical trials of antimicrobial-resistant pathogens M Paul, Y Dishon-Benattar, Y Dickstein, D Yahav JAC-antimicrobial resistance 5 (1), dlad005, 2023 | 1 | 2023 |
| In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections A Nutman, E Temkin, J Lellouche, N Rakovitsky, A Hameir, G Daikos, ... Clinical Microbiology and Infection 28 (1), 73-78, 2022 | 1 | 2022 |
| Longer-term Mortality and Kidney Outcomes of Participants in the Combination Antibiotics for Methicillin-Resistant Staphylococcus aureus (CAMERA2) Trial: A Post … A Legg, MA Roberts, J Davies, A Cass, N Meagher, A Sud, V Daitch, ... Open forum infectious diseases 10 (7), ofad337, 2023 | | 2023 |
| The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe (vol 75, pg 2027, 2022) N Anagnostou, S Archuleta, E Athan, L Barina, E Best, M Bloomfield, ... OXFORD UNIV PRESS INC, 2023 | | 2023 |
| Choosing Wisely Antibiotic Treatment to Reduce Futile Therapy at End of Life: Cost-Benefit Model Development and Testing YD Benattar PQDT-Global, 2020 | | 2020 |
| Low Doses of Colistimethate: Don't Rush In! Reply M Paul, D Yahav, YD Benattar, L Leibovici CLINICAL INFECTIOUS DISEASES 64 (5), 696-696, 2017 | | 2017 |
| The Safety and Effectivennes of High-Dose Colistin: Prospective Observatory Study YD Benattar PQDT-Global, 2014 | | 2014 |
